



(51) International Patent Classification:

A61K 31/506 (2006.01) A61K 9/36 (2006.01)
A61K 9/24 (2006.01) A61P 25/18 (2006.01)
A61K 9/32 (2006.01)

(21) International Application Number:

PCT/US2024/021265

(22) International Filing Date:

25 March 2024 (25.03.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/455,403 29 March 2023 (29.03.2023) US

(71) Applicants: **MERCK SHARP & DOHME LLC** [US/US]; 126 East Lincoln Avenue, Rahway, New Jersey 07065 (US). **MERCK SHARP & DOHME (UK) LIMITED** [GB/GB]; Hertford Road, Hoddesdon Hertfordshire EN11 9BU (GB).

(72) Inventors: **DINUNZIO, James C.**; 126 East Lincoln Avenue, Rahway, New Jersey 07065 (US). **HARRIS, David**; 126 East Lincoln Avenue, Rahway, New Jersey 07065 (US). **KUMAR, Maria Sharlini**; Hertford Road, Hoddesdon Hertfordshire EN11 9BU (GB). **POLLITT, Michael John**; Hertford Road, Hoddesdon Hertfordshire EN11 9BU (GB). **RADOJEVIC, Jovana**; 126 East Lincoln Avenue, Rahway, New Jersey 07065 (US). **TERIFE, Graciela**; 126 East Lincoln Avenue, Rahway, New Jersey 07065 (US).

(74) Agent: **AYLER, Sylvia A.**; 126 East Lincoln Avenue, Rahway, New Jersey 07065 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,

(54) Title: CONTROLLED RELEASE PDE10A FORMULATIONS




FIG. 1

(57) Abstract: The present disclosure relates generally to treatment of central nervous system disorders associated with phosphodiesterase 10A (PDE10A) such as schizophrenia, bipolar disease, and Alzheimer's disease, as therapeutics for neurological and psychiatric disorders. This disclosure provides controlled-release formulations of 2-methyl-N-((5-methyl-1,3,4-thiadiazol-2-yl)methyl)-6-(((1S,2S)-2-(5-methylpyridin-2-yl)cyclopropyl)methoxy)pyrimidin-4-amine (Compound A) and their use in the treatment of schizophrenia and other psychiatric disorders that improves the tolerability profile.

[Continued on next page]

RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to the identity of the inventor (Rule 4.17(i))*
- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*